X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Merck to Acquire Verona

    Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

    Emerging Oral Small Molecule Drugs

    Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    FDA Approves Oral Therapy for Treating Hereditary Angioedema

    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development

Biotium Debuts Novel Fluorescent Dyes that Push Emission Further into the Infrared Spectrum

Content Team by Content Team
29th September 2021
in Drug Development, News
DNA

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Biotium, a leading supplier and inventor of fluorescent probes for life science research, announces the release of infrared CF®850 and CF®870 dyes. These novel long wavelength dyes are the first commercially available fluorescent dyes with emission maxima greater than 850 nm, allowing researchers to further investigate the “final frontier” of infrared wavelengths for life science research applications. Due to their excellent brightness, aqueous solubility, and exceptional infrared properties, CF®850 and CF®870 represent a true breakthrough in synthetic fluorescent probes.

Infrared (IR) and near-infrared (near-IR) probes offer several advantages over probes in the visible light region. Their superior sensitivity, linearity, tissue penetration, and minimal autofluorescence background are beneficial for in vivo imaging, western blotting, and microscopy. In addition, the availability of probes that extend further into IR wavelengths enables greater multiplexing options for flow cytometry. Recently, the benefits of long wavelength fluorescence have spurred the development of flow cytometers and imaging instrumentation equipped with near-IR laser diodes and detection systems. Biotium’s CF®850 and CF®870 dyes aim to accommodate research that takes advantage of these hardware advancements by offering long wavelength emission beyond any commercially available IR probe.

CF®850 and CF®870 are optimally designed for the 808 nm laser but may also be excited by the 785 nm laser. They are currently available as stable amine-reactive TFP (tetrafluorophenyl) esters but will be available soon as labels for commonly used antibodies, bioconjugates, and with Biotium’s easy-to-use Mix-n-Stain™ Antibody Labeling Kits.

CF®850 and CF®870 are part of Biotium’s family of patented pegylated CF® Dyes and adds to Biotium’s growing list of novel long wavelength dyes for life science research. Biotium’s IR and near-IR dyes also include CF®700, CF®750, CF®770, CF®790, CF®800, CF®820, and the recently released flow cytometry tandem dyes APC-CF®750T and APC-CF®790T.

About Biotium
Biotium is a leading life science reagent manufacturer and supplier devoted to providing high-quality and innovative fluorescent tools that fuel scientific discovery. Our collaborative team of experienced chemists and biologists, who are at the forefront of fluorescent dye design, apply chemistry-based principles toward producing solutions for unmet challenges in life science and medical research. Since its founding in 2001, Biotium has developed over 30 patented technologies that have been licensed out to leading life science technology companies worldwide.

Previous Post

CPhI Report predicts record EBITDAs for CDMOs in 2022

Next Post

Chemspec Digital 2021 scored with quality and in-depth expert talks

Related Posts

Merck to Acquire Verona
Drug Development

Merck to Acquire Verona Pharma in $10B Deal Boosts COPD Drug

21st July 2025
ChiRhoClin LogiCare3PL Partners for Drug Distribution
News

ChiRhoClin, LogiCare3PL Partners for Drug Distribution

21st July 2025
Emerging Oral Small Molecule Drugs
Drug Development

Emerging Oral Small-Molecule Drugs for Ultra-Rare Diseases

21st July 2025
Thermo Fisher and Sanofi Partners
Manufacturing

Thermo Fisher and Sanofi Partners for US Drug Manufacturing

21st July 2025
EMA Recommendations to Secure Anti D Immunoglobulins Supply
News

EMA Recommendations to Secure Anti-D Immunoglobulins Supply

15th July 2025
FDA Approves Oral Therapy for Treating Hereditary Angioedema
FDA Approvals

FDA Approves Oral Therapy for Treating Hereditary Angioedema

15th July 2025
Next Post
Chemspec Digital 2021 scored with quality and in-depth expert talks

Chemspec Digital 2021 scored with quality and in-depth expert talks

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In